This page contains a Flash digital edition of a book.
Drug Discovery


biology may enable one-hour iterations, or up to 168 iterations in a week. Given a current estimate of at least one week per iteration in a more tradi- tional pharmaceutical discovery environment, this clearly represents a paradigm shift in the early stages of small molecule discovery from initial hits to late stage molecules for final optimisation. Consequently, integrated platforms will soon be capable of the very rapid generation of a wide range of chemical structures and corresponding biological activity data to potentially transform modern drug discovery. The acid test will now be the demonstra- tion that a development candidate can be discov- ered in a dramatically shortened timescale. DDW


Following a BSc in chemistry from the University of Durham and a PhD in organic synthesis from Exeter, Dave spent two years in the USA working in the labs of Prof Philip D Magnus FRS. Starting his career as a medicinal chemist with Celltech, Dave rapidly developed an interest in drug discov- ery technologies and made the move to Chiroscience in Cambridge to head up its combi- natorial chemistry effort. After the acquisition of Chiroscience by Celltech he continued to strength- en both his scientific and management skills lead- ing the Exploratory Chemistry section at the Cambridge site, responsibilities including high throughput chemistry, analytical chemistry and the computational chemistry group. When UCB acquired Celltech in 2004, Dave had the opportu- nity to play a key role in small molecule discovery technologies and joined Cyclofluidic as Chief Operating Officer from UCB where he was most recently Director, Technology within Research.


Dr J Mark Treherne has been actively involved in the biopharmaceutical industry for 25 years and was a co-founder and Chief Executive of Cambridge Drug Discovery Limited (CDD), lead- ing the acquisition of CDD for £28 million by AiM-listed BioFocus plc, where he then became a Commercial Director of BioFocus, driving signifi- cant growth of its profitable services business. Since leaving his full-time position at BioFocus plc in February 2002 to remain on the Board as a non- executive director, Mark has now served on the Boards of more than 10 private and public bio- pharmaceutical companies. In addition to Cyclofluidic, he is currently on the Boards of NeuroDiscovery Limited, Domain Pharmaceuticals SA, Population Genetics Technologies Limited, Senexis Limited and Xention Limited. Dr Treherne has now helped raise more than £90 million for various biophar- maceutical businesses over the past 10 years. Dr Treherne was also formerly Chairman of ERBI Limited, which is a not-for-profit organisation that represents the biotechnology companies based around Cambridge in the East of England, UK. Dr Treherne initially trained as a neuroscientist and electrophysiologist at Cambridge University and previously led the Neurodegeneration research group at Pfizer’s research facility.


Dr Dave M Parry has more than 17 years’ experi- ence in pharmaceutical discovery gained within the biotech and biopharmaceutical industry.


Drug Discovery World Summer 2011


Prior to joining Cyclofluidic as Chief Technology Officer, Chris Selway was employed at Pfizer Global R&D in Sandwich, UK as a Senior Principal Scientist. He brings considerable experi- ence in pharmaceutical discovery technologies development and had been leading the develop- ment of a microfluidic synthesis-assay platform for hit-to-lead discovery within Pfizer. Following grad- uation with a BSc in Chemistry from Loughborough University, Chris has accumulated 26 years of experience in pharmaceutical research at Pfizer, and has broad knowledge and expertise in chemical technology development and modern organic synthesis techniques. He was a founder member of the Pfizer Library Design and Production group with responsibility for develop- ment and implementation of automated systems for synthesis, analysis and purification of com- pound libraries. In 1997 Chris was awarded a Pfizer Individual Achievement Award for out- standing contribution to parallel synthesis and chemistry automation and in 2000 was awarded a Pfizer Team Achievement Award as member of the Autopurification Team for innovative design and delivery of a world leading system for the efficient purification of library compounds. More recently Chris has focused on applying flow chemistry and microfluidic technologies to enhance the drug dis- covery process. Externally, Chris is currently col- laborating with Professor Steve Ley at Cambridge University, with a focus on flow chemistry; and is a member of the organising committee of the United Kingdom Automated Synthesis Forum (UKASF).


References 1 See for example: Kymouse platform (www.kymab.com); UCB Selective Lymphocyte Antibody Method (http://www.ucb.com/rd/scienc e/innovative-proprietary/ucb- slam). 2Wong-Hawkes, SYF, Matteo, JC, Warrington, BH and White, JD. Microreactors as new tools for drug discovery and development. Ernst Schering Found Symp Proc. 2006;(3):39- 55. 3 For a recent review see Wiles, Charlotte and Watts, Paul. Recent advances in micro reaction technology Chem Commun. 2011, 47, 6512-6535. 4 DuBois, D. An apparatus for the study of rapid chemical reactions J Biol Chem 137 (1): 123-137 (1941). 5 deBoer, AR, Lingeman, H, Niessen, WM, Irth, H. Mass spectrometry-based biochemical assays for enzyme- inhibitor screening. 6 Hadd, Andrew G, Raymond, Daniel E, Halliwell, John W, Jacobson, Stephen C and Ramsey, J Michael. Microchip Device for Performing Enzyme Assays Anal chem. 1997, 69, 3407-3412. Hadd, Andrew G, Jacobson, Stephen C and Ramsey, J. Michael. Microfluidic assays of acetylcholinesterase inhibitors Anal Chem 1999 71 5206-5212. 7 Huber, Walter. SPR-Based Direct Binding Assays in Drug Discovery. Label-Free Technologies for Drug Discovery, Editors: Matthew Cooper, Lorenz M. Mayr. Wiley 2011. 8 Lipinski, CA, Lombardo, F, Dominy, BW, Feeney, PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23, 1997, 3- 25. 9 For example Labview from National Instruments. 10 For example Knime (www.knime.org) and Pipeline Pilot (www.accelrys.com/ products/pipeline-pilot).


29


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92